摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(3-溴苯基)-5-甲基-1,2,4-恶二唑 | 160377-57-1

中文名称
3-(3-溴苯基)-5-甲基-1,2,4-恶二唑
中文别名
3-(3-溴苯基)-5-甲基-1,2,4-噁二唑
英文名称
3-(3-bromophenyl)-5-methyl-1,2,4-oxadiazole
英文别名
——
3-(3-溴苯基)-5-甲基-1,2,4-恶二唑化学式
CAS
160377-57-1
化学式
C9H7BrN2O
mdl
MFCD08087563
分子量
239.071
InChiKey
GTYLSVIVKRJHIQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    81 °C

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.111
  • 拓扑面积:
    38.9
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090

SDS

SDS:6f31332e0633d98fc8ba99e267378f7e
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-(3-Bromophenyl)-5-methyl-1,2,4-oxadiazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-(3-Bromophenyl)-5-methyl-1,2,4-oxadiazole
CAS number: 160377-57-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H7BrN2O
Molecular weight: 239.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(3-溴苯基)-5-甲基-1,2,4-恶二唑tris-(dibenzylideneacetone)dipalladium(0) 、 oxone||potassium monopersulfate triple salt 、 N,N-二异丙基乙胺4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下, 以 甲苯乙腈 为溶剂, 反应 6.0h, 生成 C13H14N2O5S
    参考文献:
    名称:
    在DNA上合成磺酰胺的策略。
    摘要:
    据报道,一种有效的方法是在温和条件下,在碘的存在下,由亚磺酸或亚磺酸钠和胺在DNA上合成磺酰胺。该方法证明了通过利用新型碳酸钠-亚磺酸钠双功能试剂类别在DNA上形成磺酰胺的范围有了很大的扩展。
    DOI:
    10.1021/acs.orglett.9b03843
  • 作为产物:
    描述:
    间溴苯甲腈吡啶羟胺 作用下, 以 乙醇 为溶剂, 反应 27.0h, 生成 3-(3-溴苯基)-5-甲基-1,2,4-恶二唑
    参考文献:
    名称:
    钴(III)催化的恶二唑定向CH活化反应合成1-氨基异喹啉
    摘要:
    在C–H功能化中,芳香杂环已被确认为有效的导向基团(DG),但在最终产品中可保留为不希望的大取代基。在本文中,我们报告了基于乙二唑的芳烃C–H与炔烃偶联的Co(III)催化的1-氨基异喹啉合成策略,以及随后的氧化还原中性C–N环化反应。这种基于N–O键的不稳定方案允许耐受各种官能团。
    DOI:
    10.1021/acs.orglett.7b01119
点击查看最新优质反应信息

文献信息

  • Imidazole hydrochloride promoted synthesis of 3,5-disubstituted-1,2,4-oxadiazoles
    作者:Xuetong Wang、Yin Wang、Xiaoling Liu、Tingshu He、Lingli Li、Huili Wu、Shangjun Zhou、Dan Li、Siwei Liao、Ping Xu、Xing Huang、Jianyong Yuan
    DOI:10.1016/j.tet.2021.132496
    日期:2021.11
    Imidazole hydrochloride as an additive promotes the reaction of amidoximes and DMA derivatives to generated 3,5-disubstituted-1,2,4-oxadiazoles in low to excellent yields without the use of coupling reagents, oxidants, strong acids or bases and other additives.
    咪唑盐酸盐作为添加剂促进酰胺DMA生物反应生成 3,5-二取代-1,2,4-恶二唑,收率从低到高,无需使用偶联剂、氧化剂、强酸或强碱和其他添加剂。
  • [EN] BIARYL PYRAZOLES AS NRF2 REGULATORS<br/>[FR] BIARYL PYRAZOLES UTILISÉS COMME RÉGULATEURS DE NRF2
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2017060854A1
    公开(公告)日:2017-04-13
    The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    本发明涉及双芳基吡唑化合物、它们的制备方法、含有它们的药物组合物及其作为NRF2调节剂的应用。
  • [EN] BIARYL CARBOXAMIDES<br/>[FR] BIARYL CARBOXAMIDES
    申请人:MERCK SHARP & DOHME
    公开号:WO2010077624A1
    公开(公告)日:2010-07-08
    This invention provides compounds of Formula (I) which are PAFR antagonists: Formula (I) and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful for treating or ameliorating pain, e.g. inflammatory pain and/or nociceptive pain, and for treating or ameliorating autoimmune and/or inflammatory diseases, among other conditions.
    这项发明提供了化合物的公式(I),这些化合物是PAFR拮抗剂:公式(I)及其药用盐。这些化合物可用于治疗PAF介导的疾病,并可用于治疗动脉粥样硬化并预防或减少动脉粥样硬化疾病事件的风险的方法。这些化合物还可用于治疗或缓解疼痛,例如炎症性疼痛和/或伤害性疼痛,并用于治疗或缓解自身免疫和/或炎症性疾病等其他疾病。
  • [EN] SUBSTITUTED 6-MEMBERED ARYL OR HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES ARYLE OU HÉTÉROARYLE À 6 CHAÎNONS SUBSTITUÉS DE RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE
    申请人:MERCK SHARP & DOHME
    公开号:WO2018085170A1
    公开(公告)日:2018-05-11
    The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    本公开涉及公式(I)的化合物,这些化合物可用作α7 nAChR的调节剂,包含这些化合物的组合物,以及利用这些化合物预防、治疗或改善疾病,特别是中枢神经系统疾病,如阿尔茨海默病、帕森病和精神分裂症,以及L-多巴引起的运动障碍和炎症。
  • [EN] M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR D'ACETYLCHOLINE MUSCARINIQUE M3
    申请人:GLAXO GROUP LTD
    公开号:WO2005094835A1
    公开(公告)日:2005-10-13
    Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
    提供了肌氨酸乙酰胆碱受体拮抗剂及其使用方法。
查看更多